

Cannabis-based medicinal products

Consultation on draft guideline – deadline for comments 17:00 on 05/09/2019 email: CannabisMedUse@nice.org.uk

	<p>Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.</p> <p>We would like to hear your views on the draft recommendations presented in the guideline, and any comments you may have on the rationale and impact sections in the guideline and the evidence presented in the evidence reviews documents. We would also welcome views on the Equality Impact Assessment.</p> <p>In addition to your comments below on our guideline documents, we would like to hear your views on these questions:</p> <ol style="list-style-type: none">1. Which areas will have the biggest impact on practice and be challenging to implement? Please say for whom and why.2. Would implementation of any of the draft recommendations have significant cost implications?3. What would help users overcome any challenges? (For example, existing practical resources or national initiatives, or examples of good practice.) <p>See section 3.9 of Developing NICE guidance: how to get involved for suggestions of general points to think about when commenting.</p>
Organisation name – Stakeholder or respondent (if you are responding as an individual rather than a registered stakeholder please leave blank):	Royal College of Physicians and Surgeons of Glasgow
Disclosure Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry.	None
Name of commentator person completing form:	Dr Richard Hull, Honorary Secretary, in consultation with experts within the field

Please return to: CannabisMedUse@nice.org.uk

Cannabis-based medicinal products

Consultation on draft guideline – deadline for comments 17:00 on 05/09/2019 email: CannabisMedUse@nice.org.uk

Type		[office use only]		
Comment number	Document [guideline, evidence review A, B, C etc., methods or other (please specify which)]	Page number Or ' <u>general</u> ' for comments on whole document	Line number Or ' <u>general</u> ' for comments on whole document	Comments
Insert each comment in a new row. Do not paste other tables into this table, because your comments could get lost – type directly into this table.				
1	Cannabis-based medical products draft guidance	General	General	<p>The Royal College of Physicians and Surgeons of Glasgow was founded in 1599 to improve quality and practice of Medicine.</p> <p>The College although based in Glasgow represents Fellows and Members throughout the United Kingdom. While NICE has a remit for England, many of the recommendations are applicable to all devolved nations including Scotland. They should be considered by the relevant Ministers of the devolved governments</p> <p>The College welcomes this document in area where hitherto there has been little expert guidance. It notes that this topic has received publicity for various quarters in the public domain. This document sets out very sensible, pragmatic and evidence-based guidance for practitioners in an area where such guidance is needed. It is well structured, clear and authoritative.</p> <p>Areas which will be addressed separately and hence fall outside the scope of this document are clearly defined.</p>
2	Cannabis-based medical products draft	7	11	Both “history of” and “current” substance misuse are of relevance to prescribing in this context and this should be explicit.

Please return to: CannabisMedUse@nice.org.uk

Cannabis-based medicinal products

Consultation on draft guideline – deadline for comments 17:00 on 05/09/2019 email: CannabisMedUse@nice.org.uk

	guidance			
3	Cannabis-based medical products draft guidance	7	24	Given the possibility of multiple drug misuse, and the inherent uncertainty over active moieties in illicit drugs, there should be explicit guidance to desist from ingestion of all illicit drugs rather than just those which (may) contain cannabis.

Insert extra rows as needed

Checklist for submitting comments

- Use this comment form and submit it as a **Word document (not a PDF)**.
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include **page and line number (not section number)** of the text each comment is about.
- Combine all comments from your organisation into 1 response. **We cannot accept more than 1 response from each organisation.**
- Do not paste other tables into this table – type directly into the table.
- **Mark any confidential information or other material that you do not wish to be made public. Also, ensure you state in your email to NICE that your submission includes confidential comments.**
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, comment forms **do not include attachments** such as research articles, letters or leaflets (for copyright reasons). We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.
- **We do not accept comments submitted after the deadline stated for close of consultation.**

You can see any guidance that we have produced on topics related to this guideline by checking [NICE Pathways](#).

Note: We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees. Further information regarding our privacy information can be found at our [privacy notice](#) on our website.

Please return to: CannabisMedUse@nice.org.uk

Cannabis-based medicinal products

NICE National Institute for
Health and Care Excellence

Consultation on draft guideline – deadline for comments 17:00 on 05/09/2019 email: CannabisMedUse@nice.org.uk

Please return to: CannabisMedUse@nice.org.uk